Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Nathan Connell on Conversion from Eptacog Alfa to Beta
Nathan Connell/LinkedIn
Dec 15, 2025, 12:34

Nathan Connell on Conversion from Eptacog Alfa to Beta

Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:

”New Research: Real-World Evidence on Recombinant Factor VIIa Substitution

I’m excited to share our team’s latest publication in Clinical Applied Thrombosis Clinical and Applied Thrombosis/Hemostasis.

We conducted a retrospective evaluation of our conversion from eptacog alfa (NovoSeven) to eptacog beta (Sevenfact) to assess both clinical safety and financial impact at Brigham and Women’s Hospital.

Key Findings:

  • Safety: The transition to eptacog beta showed no adverse thrombotic events across the patient cohort.
  • Efficacy: Effective management was maintained for indications including hemophilia bleeding and peri-procedural management.
  • Impact: The medication use evaluation identified an estimated cost avoidance of $554,400 over 12 months.

This study supports the viability of therapeutic interchange for rFVIIa products, offering a pathway for other institutions to maintain high-quality care while optimizing costs.”

Read the full article here.

Article: Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center

Authors: George AR, Sylvester KW, Kanaan DM, Reddy P, Fanikos JR, Connors JM, Connell NT

Nathan Connell on Conversion from Eptacog Alfa to Beta

Stay updated on all scientific advances with Hemostasis Today.

bleeding disorders Brigham and Women's Hospital Connell NT Connors JM eptacog alfa Eptacog Beta Fanikos JR George AR Health Hematology Hemophilia Hemostasis Hemostasis Today Kanaan DM Medicine NovoSeven Reddy P Sevenfact Sylvester KW
NewsFeed